Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lung Neoplasms 2Glioma 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Sarcoma 1Rhabdomyosarcoma 1Pheochromocytoma 1Paraganglioma 1Papillary renal cell carcinoma, sporadic 1Pancreatic Ductal Adenocarcinoma 1Osteoradionecrosis 1Mouth Neoplasms 1Melanoma 1Hereditary leiomyomatosis and renal cell cancer 1Gliosarcoma 1Fallopian Tube Mucinous Adenocarcinoma 1Craniopharyngioma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Brain Neoplasms 1

Interventions

Specimen Handling 6pembrolizumab 4enfortumab vedotin 4Magnetic Resonance Spectroscopy 4Gemcitabine 3cabozantinib 2Nivolumab 2Carboplatin 2Biopsy 2relatlimab 1eribulin 1erdafitinib 1avelumab 1atezolizumab 1Watchful Waiting 1Standard of Care 1Practice Guidelines as Topic 1Plasmapheresis 1Plasma Exchange 1Observation 1Lenalidomide 1Ipilimumab 1Doxorubicin 1Cystoscopy 1Contrast Media 1Cisplatin 1Central Venous Catheters 1CTLA-4 Antigen 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ureteral Neoplasms × Contrast Media × 90 days × Clear all
NCT03237780 2026-05-13

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
72 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡